Phio Pharmaceuticals Corp. announces a significant advancement in the development of PH-762, a potential non-surgical treatment for skin cancers.
The company's nonclinical protocol study design for PH-762 has been accepted by the FDA, with the study set to commence in the first quarter of 2026.
Positive interim safety and efficacy results have been reported in the Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer.
FDA Acceptance
FDA has accepted Phio Pharmaceuticals' nonclinical protocol study design for PH-762, indicating progress towards regulatory approval.
Positive Trial Results
Interim results of the Phase 1b dose escalation trial showed promising safety and efficacy outcomes for PH-762 in treating skin cancers.
Commercial Drug Product
Initiatives are ongoing to deliver a commercially viable drug product meeting FDA standards in 2026.
- The completion of the toxicology study is a crucial step towards progressing PH-762 towards an NDA approval.
- Positive responses in the Phase 1b trial indicate the potential effectiveness of PH-762 as a treatment for various skin cancers.
Phio Pharmaceuticals' advancements in drug development for PH-762 demonstrate promising prospects in the field of immuno-oncology therapeutics. The company's commitment to innovation and regulatory compliance positions it well for future success in the pharmaceutical industry.